UM

Browse/Search Results:  1-10 of 140 Help

Selected(0)Clear Items/Page:    Sort:
Polycyclic polyprenylated acylphloroglucinols from the pericarps of Garcinia multiflora champ. ex Benth. with cytotoxic property Journal article
Cao, Jun, Lyu, Wen Yu, Zhang, Yujia, Su, Zhicheng, Li, Ting, Zhang, Qingwen, Gan, Lishe, Lu, Jin Jian, Lin, Ligen. Polycyclic polyprenylated acylphloroglucinols from the pericarps of Garcinia multiflora champ. ex Benth. with cytotoxic property[J]. Phytochemistry, 2024, 228, 114242.
Authors:  Cao, Jun;  Lyu, Wen Yu;  Zhang, Yujia;  Su, Zhicheng;  Li, Ting; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.2/3.4 | Submit date:2024/09/03
Apoptosis  Cell Cycle Arrest  Clusiaceae  Cytotoxicity  Garcinia Multiflora  Polycyclic Polyprenylated Acylphloroglucinols  
Uncover the anticancer potential of lycorine Journal article
Zhang, Yan Ming, Li, Ting, Xu, Chun Cao, Qian, Jia Yu, Guo, Hongwei, Zhang, Xiaolei, Zhan, Zha Jun, Lu, Jin Jian. Uncover the anticancer potential of lycorine[J]. Chinese Medicine (United Kingdom), 2024, 19(1), 121.
Authors:  Zhang, Yan Ming;  Li, Ting;  Xu, Chun Cao;  Qian, Jia Yu;  Guo, Hongwei; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0 | Submit date:2024/10/10
Anticancer Mechanism  Lycorine  Lycorine Hydrochloride  Pharmacokinetics  Target  
Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products Journal article
Zhang, Le Le, Zhang, Du Juan, Shi, Jia Xin, Huang, Mu Yang, Yu, Jia Mei, Chen, Xu Jia, Wei, Xiao, Zou, Liang, Lu, Jin Jian. Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products[J]. Phytomedicine, 2024, 132, 155828.
Authors:  Zhang, Le Le;  Zhang, Du Juan;  Shi, Jia Xin;  Huang, Mu Yang;  Yu, Jia Mei; et al.
Favorite | TC[Scopus]:1  IF:6.7/6.2 | Submit date:2024/07/04
Cancer Therapy  Immunogenic Cell Death  Natural Products  Regulated Cell Death  Tumor Immune Microenvironment  
Voluntary forward-looking disclosures and default risk pricing Journal article
Chen, C., Wei, M.H., Zhang, H., Yan, J.J.. Voluntary forward-looking disclosures and default risk pricing[J]. Accounting and Business Research, 2024.
Authors:  Chen, C.;  Wei, M.H.;  Zhang, H.;  Yan, J.J.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:2.0/2.8 | Submit date:2023/12/17
Management Forecast Reports  Multi-modal Information  Default Risk Pricing  Credit Default Swap  
Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma Journal article
Zhang, Qi Yi, Ding, Wen, Mo, Jian Shan, Ou-yang, Shu Min, Lin, Zi You, Peng, Ke Ren, Liu, Guo Pin, Lu, Jin Jian, Yue, Pei Bin, Lei, Jin Ping, Wang, Yan Dong, Zhang, Xiao Lei. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma[J]. ACTA PHARMACOLOGICA SINICA, 2024.
Authors:  Zhang, Qi Yi;  Ding, Wen;  Mo, Jian Shan;  Ou-yang, Shu Min;  Lin, Zi You; et al.
Favorite | TC[WOS]:5 TC[Scopus]:6  IF:6.9/7.6 | Submit date:2024/05/16
Acquired Sorafenib-resistance  Antisense Oligonucleotide  Hepatocellular Carcinoma  Stat3  
Paraptosis: a non-classical paradigm of cell death for cancer therapy Review article
2024
Authors:  Xu, Chun cao;  Lin, Yi fan;  Huang, Mu yang;  Zhang, Xiao lei;  Wang, Pei; et al.
Favorite | TC[WOS]:20 TC[Scopus]:17  IF:6.9/7.6 | Submit date:2024/02/22
Cancer Therapy  Endoplasmic Reticulum  Er Stress  Mitochondria  Paraptosis  
Combination strategies for first-line treatment of patients with unresectable hepatocellular carcinoma: prospect of natural products Other
2024-01-01
Authors:  ZHANG, Lele;  LU, Jinjian
Favorite | TC[WOS]:4 TC[Scopus]:4 | Submit date:2024/02/22
Combination Strategies  Immunotherapy  Natural Products  Pd-1/pd-l1  Unresectable Hepatocellular Carcinoma  
The role of major customers' qualitative forward-looking information in affecting suppliers' future operating performance (Conditionally Accepted) Journal article
Chen, C., Yuen, C.Y., Zhang, H., Yan, J.J.. The role of major customers' qualitative forward-looking information in affecting suppliers' future operating performance (Conditionally Accepted)[J]. Accounting Forum, 2023.
Authors:  Chen, C.;  Yuen, C.Y.;  Zhang, H.;  Yan, J.J.
Favorite |   IF:2.8/4.0 | Submit date:2023/12/17
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia Journal article
Mo, Jianshan, Deng, Lin, Peng, Keren, Ouyang, Shumin, Ding, Wen, Lou, Linlin, Lin, Ziyou, Zhu, Jianzheng, Li, Jingwei, Zhang, Qiyi, Wang, Pengyan, Wen, Yuanzhen, Chen, Xiaobing, Yue, Peibin, Lu, Jin Jian, Zhu, Kai, Zheng, Yongjiang, Wang, Yuanxiang, Zhang, Xiaolei. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia[J]. Journal of Hematology & Oncology, 2023, 16(1), 15.
Authors:  Mo, Jianshan;  Deng, Lin;  Peng, Keren;  Ouyang, Shumin;  Ding, Wen; et al.
Favorite | TC[WOS]:15 TC[Scopus]:14  IF:29.5/26.9 | Submit date:2023/03/06
Aml  Immunotherapy  Stat3 Inhibitor  Vista  
Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer Journal article
Wang, Xianzhe, Shi, Wei, Wang, Xumei, Lu, Jin Jian, He, Ping, Zhang, Hongjie, Chen, Xiuping. Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer[J]. Cell Death Discovery, 2023, 9(1), 355.
Authors:  Wang, Xianzhe;  Shi, Wei;  Wang, Xumei;  Lu, Jin Jian;  He, Ping; et al.
Favorite | TC[WOS]:6 TC[Scopus]:6  IF:6.1/6.0 | Submit date:2024/01/02